Singulair gets MedWatch alert for suicide risk
FDA will likely need nine months to review data potentially linking Merck's asthma treatment Singulair (motelukast) to behavior/mood changes, suicidality and suicide, the agency says in a March 27 MedWatch alert. FDA attributes the lengthy evaluation time to the complexity of the analyses. Merck updated its label four times in the past year to add post-marketing adverse events including tremor, depression, suicidality and, most recently, anxiousness
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.